Isotretinoin Pregnancy Prevention Programme — GPhC CRA MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: C — Do not dispense until Pregnancy Prevention Programme timing requirements are satisfied
Isotretinoin is highly teratogenic and dispensing for patients who can become pregnant must comply with Pregnancy Prevention Programme requirements, including strict timing around pregnancy testing and prescription validity. A general 28-day prescription validity approach is not enough for this medicine. Verbal reassurance does not replace documented programme requirements. Folic acid does not mitigate isotretinoin teratogenicity.
Reference: BNF; MHRA Drug Safety Update